Pharmacogenomics to Benefit from Steven Burrill s New $300M-$500M Life Sciences Venture Capital Fund | GenomeWeb

NEW YORK, Jan. 7 (GenomeWeb News) - Burrill & Company, a San Francisco-based life sciences merchant bank, is launching a $300-million to $500-million venture capital fund dedicated to biotechnology, personalized medicine, new diagnostics, and devices.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.